High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma
oleh: Jean El-Cheikh, Mauricette Michallet, Arnon Nagler, Hugues de Lavallade, Franck E. Nicolini, Avichai Shimoni, Catherine Faucher, Mohamad Sobh, Daniela Revesz, Izhar Hardan, Sabine Fürst, Didier Blaise, Mohamad Mohty
| Format: | Article |
|---|---|
| Diterbitkan: | Ferrata Storti Foundation 2008-03-01 |
Deskripsi
We describe the results of 37 myeloma patients who received bortezomib following reduced intensity allogeneic stem cell transplantation (RIC-allo-SCT). Grade 1–2 peripheral neuropathy (35%), mild thrombocytopenia (24%) and fatigue (19%) were the most frequent adverse events, while there was no worsening of graft-vs-host disease symptoms. Twenty-seven patients (73%; 95% CI, 59–87%) achieved an objective response. With a median follow-up of 9 months from bortezomib initiation, the estimate of overall survival was 65% at 18 months while this was significantly higher (p=0.002) in the 27 patients achieving an objective response, suggesting that bortezomib is a safe and efficient option for myeloma patients after RIC-allo-SCT.